EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease

Paul Rolan, Elizabeth Doolin, Dharam Paul, Julia Crossman, Michael Odontiadis, Philippe Danjou, Mark Smith, Spyros Papapetropoulos

Clinical Pharmacology in Drug Development · 2026-02 · 15 (2)

DOI: 10.1002/cpdd.1609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 27.09.2025. Verfasst von Paul Rolan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Consulting and University of Adelaide Medical School, Adelaide, Australia. Hauptthemen laut MEDLINE: alpha7 Nicotinic Acetylcholine Receptor, Anti-Anxiety Agents, Mental Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha‐7 nicotinic acetylcholine receptor (α7 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention, cognition, or memory impairment, negative effects on mood or emotional stability, sedation, or addiction, ruling out undesirable side effects of known anxiolytic compounds. In healthy volunteers, target engagement at the α7 nAChR was demonstrated in a nicotine shift assay using quantitative electroencephalography, and BNC210 demonstrated improvement in panic‐like symptoms in a cholecystokinin tetrapeptide panic model. Initial clinical trials used an aqueous suspension formulation of BNC210 to cover a wide dosage range; however, its pharmacokinetic parameters were consistent with solubility‐limited absorption and a significant food effect. A dispersible tablet formulation was then developed with improved bioavailability and is being used in Phases 2 and 3 clinical trials. Collectively, the Phase 1 data demonstrated desired properties of BNC210 supporting proof‐of‐concept clinical trials. BNC210 is currently being developed for acute, as‐needed treatment of social anxiety disorder and chronic treatment of post‐traumatic stress disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha7 Nicotinic Acetylcholine ReceptorAnti-Anxiety AgentsMental DisordersHumansAllosteric RegulationProof of Concept StudyAnimalsClinical Trials, Phase I as TopicMaleAdult

Stichwörter der Autor:innen

BNC210alpha‐7 nicotinic acetylcholine receptorclinical pharmacologynegative allosteric modulationpsychiatry

Substanzen

alpha7 Nicotinic Acetylcholine ReceptorAnti-Anxiety AgentsChrna7 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology Consulting and University of Adelaide Medical School, Adelaide, Australia.
  • Clinical, Neuphoria Therapeutics Inc., Adelaide, Australia.
  • Principal, Danjou Consulting, Paris, France.
  • Medical, Neuphoria Therapeutics Inc., Boston, Massachusetts, USA.

Zitieren

APA

Rolan, P., Doolin, E., Paul, D., Crossman, J., Odontiadis, M., Danjou, P., Smith, M., & Papapetropoulos, S. (2026). The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease. Clinical Pharmacology in Drug Development, 15(2). https://doi.org/10.1002/cpdd.1609

Vancouver

Rolan P, Doolin E, Paul D, Crossman J, Odontiadis M, Danjou P, et al. The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease. Clinical Pharmacology in Drug Development. 2026;15(2). doi:10.1002/cpdd.1609

BibTeX
@article{Rolan2026,
  author = {Rolan, Paul and Doolin, Elizabeth and Paul, Dharam and Crossman, Julia and Odontiadis, Michael and Danjou, Philippe and Smith, Mark and Papapetropoulos, Spyros},
  title = {The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {2},
  doi = {10.1002/cpdd.1609}
}
Kostenlos starten →